Clinical outcome in patients with intramedullary spinal cord metastases from lung cancer

C. Conill, J. Marruecos, E. Verger, J. Berenguer, F. Lomeña, J. Domingo-Domènech, J. J. Grau, F. Casas

Research output: Contribution to journalArticlepeer-review


Intramedullary spinal cord metastases (ISCM) are uncommon and present with rapidly progressing neurological deficits. The objective of this study was to determine the rate, duration of neurological response and survival after radiation therapy. We have retrospectively reviewed the clinical outcome of six cases with a diagnosis of ISCM from primary lung cancer, non-small cell (NSCLC) (n = 3) and small cell (SCLC) (n = 3). Total radiation dose ranged from 27 Gy/5 fr to 40 Gy/20 fr. Ambulation was preserved in 3 patients and partially recovered in one. Five out of the six patients (83%) showed improvement in neurological signs/symptoms with a mean duration of 17.2 days (max: 40 days; min: 6 days). Median survival time was 5 months (confidence interval (CI) 95%: 0-12) for NSCLC and 5 months (CI 95%: 4-6) for SCLC. Although radiation response rate is high, the interval free of neurological progression is very short. A therapeutic approach should be considered for each individual.

Original languageEnglish (US)
Pages (from-to)172-176
Number of pages5
JournalClinical and Translational Oncology
Issue number3
StatePublished - 2007


  • Intramedullary spinal cord metastases
  • Lung cancer
  • Magnetic resonance imaging
  • Positron emission tomography
  • Radio therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Clinical outcome in patients with intramedullary spinal cord metastases from lung cancer'. Together they form a unique fingerprint.

Cite this